First Preclinical Development Candidate for Nucleome Therapeutics - Top-Institutions - MDSpire

First Preclinical Development Candidate for Nucleome Therapeutics

First-in-class monoclonal antibody agonist program for inflammation

  • January 19, 2026

  • 2 min

Share

Top Institutions in Infectious Disease

Brief introduction explaining scope and methodology.

  • #1

    Broad Institute of MIT and Harvard
    Broad Institute of MIT and Harvard

    Cambridge, MA

    Key Differentiators

    • Genomics
    • Immunology
    • Inflammatory Disease
    • Drug Discovery

  • #2

    Stanford University School of Medicine
    Stanford University School of Medicine

    Stanford, CA

    Key Differentiators

    • Immunology
    • Autoimmune Disease
    • Monoclonal Antibody Therapeutics

  • #3

    University of Oxford
    University of Oxford

    Oxford, UK

    Key Differentiators

    • Genetics
    • Immunology
    • Inflammatory Disease

  • #4

    National Institute of Allergy and Infectious Diseases (NIAID), NIH
    National Institute of Allergy and Infectious Diseases (NIAID), NIH

    Bethesda, MD

    Key Differentiators

    • Immunology
    • Inflammatory Disease
    • Autoimmune Disorders

  • #5

    Massachusetts General Hospital (MGH) Center for Immunology and Inflammatory Diseases
    Massachusetts General Hospital (MGH) Center for Immunology and Inflammatory Diseases

    Boston, MA

    Key Differentiators

    • Immunology
    • Inflammatory Disease
    • Translational Medicine

Original Source(s)

First Preclinical Development Candidate for Nucleome Therapeutics

  • January 19, 2026

Related Content

AI Scribes: Efficiency for Whom?

Unresolved safety, privacy, and regulatory concerns may limit benefits of AI scribes for physicians and patients.

FDA Reshapes Drug Testing Approach

The agency outlined early regulatory actions supporting nonanimal methods, including draft guidance, artificial intelligence tools, and expanded use of human-relevant data models.

Melatonin-induced restoration of the intestinal mucosal barrier in inflammatory bowel disease via activation of the SIRT1-LKB1-pAMPK axis